Antibodies

8 August 2016

Coherus BioSciences Announces Positive Topline Phase Three Results for CHS-1420 (Humira® Biosimilar Candidate) in Patients with Psoriasis

5 August 2016

Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer

4 August 2016

Anthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3 Clinical Study with Blisibimod

3 August 2016

MorphoSys Successfully Completes Safety Run-in of MOR208 in L-MIND Combination Study in Patients with DLBCL

3 August 2016

Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

1 August 2016

Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma

30 July 2016

ADMA Biologics Receives Complete Response Letter from FDA for Pending Biologics License Application

28 July 2016

Chugai’s Emicizumab Showed Continued Benefits in Patients with Hemophilia A

28 July 2016

GSK in-licenses anti-IL-33R monoclonal antibody for severe asthma from Janssen

27 July 2016

GamaMabs Pharma starts phase Ia/Ib study of first-in-class monoclonal antibody GM102 in advanced gynecological cancer

26 July 2016

Daratumumab (DARZALEX®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma

25 July 2016

Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine

25 July 2016

CHMP Issues Positive Opinion for ORENCIA® (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis not Previously Treated with Methotrexate in the EU

22 July 2016

New Cell Study Presents Groundbreaking Pre-Clinical Work: Developing Immune Therapy to Potentially Treat Serious Influenza A

22 July 2016

Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab

22 July 2016

Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA

21 July 2016

Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

20 July 2016

Synaffix Achieves Significantly Improved Therapeutic Index Compared to Both FDA-Approved ADCs and Expands Its Scientific Advisory Board

20 July 2016

FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis

19 July 2016

Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood

18 July 2016

Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

18 July 2016

ArmaGen Presents Data from First Cohort of Phase 1/2a of AGT-182 for Treatment of Hunter Syndrome

18 July 2016

SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines Agency

18 July 2016

Genentech Provides Update on Phase III Study of Gazyva® in People with Previously Untreated Diffuse Large B-Cell Lymphoma

15 July 2016

International team led by Humabs BioMed identifies novel therapeutic antibody candidates isolated from Zika-infected patients

14 July 2016

Inovio Deploys DNA-based Monoclonal Antibody Technology in Quest to Cure HIV

14 July 2016

Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases

11 July 2016

Biomunex presents novel data confirming optimal drug-like properties and activity of BiXAb® antibodies

11 July 2016

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

11 July 2016

BIOCAD: Advanced rheumatoid arthritis medicine developed in Russia

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Aflibercept (Eylea) Biosimilars Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

TROP-2-Targeted Immunotherapy Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

DLL3-Targeted Immunotherapy Candidates Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Mesothelin-Targeted Immunotherapy Pipeline Review

Report Package: “Drug the Undruggable” Technologies

CD40 Agonists & CD40/L Antagonists Pipeline Review